Protalix BioTherapeutics
PLX
PLX
35 hedge funds and large institutions have $4.46M invested in Protalix BioTherapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
39% less call options, than puts
Call options by funds: $28K | Put options by funds: $46K
Holders
35
Holding in Top 10
–
Calls
$28K
Puts
$46K
Top Buyers
| 1 | +$775K | |
| 2 | +$187K | |
| 3 | +$171K | |
| 4 |
SG Americas Securities
New York
|
+$121K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$45.8K |
Top Sellers
| 1 | -$313K | |
| 2 | -$215K | |
| 3 | -$88.3K | |
| 4 |
Morgan Stanley
New York
|
-$41.3K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$38.6K |